130 related articles for article (PubMed ID: 35039231)
1. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.
Adibi M; McCormick B; Economides MP; Petros F; Xiao L; Guo C; Shah A; Kamat AM; Dinney C; Navai N; Gao J; Siefker-Radtke A; Matin SF; Campbell MT
Clin Genitourin Cancer; 2022 Apr; 20(2):176-182. PubMed ID: 35039231
[TBL] [Abstract][Full Text] [Related]
2. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
[TBL] [Abstract][Full Text] [Related]
3. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
[TBL] [Abstract][Full Text] [Related]
4. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
[TBL] [Abstract][Full Text] [Related]
8. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
10. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.
Rajput MZ; Kamat AM; Clavell-Hernandez J; Siefker-Radtke AO; Grossman HB; Dinney CP; Matin SF
Urology; 2011 Jul; 78(1):61-7. PubMed ID: 21354598
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
13. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
[TBL] [Abstract][Full Text] [Related]
14. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.
Almassi N; Gao T; Lee B; Stein RJ; Haber GP; Ornstein MC; Rini BI; Gilligan TD; Garcia JA; Stephenson AJ; Grivas P
Clin Genitourin Cancer; 2018 Dec; 16(6):e1237-e1242. PubMed ID: 30217764
[TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis.
Kim DK; Lee JY; Kim JW; Hah YS; Cho KS
Crit Rev Oncol Hematol; 2019 Mar; 135():59-65. PubMed ID: 30819447
[TBL] [Abstract][Full Text] [Related]
16. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.
Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M
Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
Seisen T; Peyronnet B; Dominguez-Escrig JL; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Cowan NC; Kaasinen E; Palou J; van Rhijn BW; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
Eur Urol; 2016 Dec; 70(6):1052-1068. PubMed ID: 27477528
[TBL] [Abstract][Full Text] [Related]
18. The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy.
Ouzzane A; Colin P; Ghoneim TP; Zerbib M; De La Taille A; Audenet F; Saint F; Hoarau N; Adam E; Azemar MD; Bensadoun H; Cormier L; Cussenot O; Houlgatte A; Karsenty G; Maurin C; Nouhaud FX; Phe V; Polguer T; Roumiguié M; Ruffion A; Rouprêt M
World J Urol; 2013 Feb; 31(1):189-97. PubMed ID: 23229227
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02.
Necchi A; Martini A; Raggi D; Cucchiara V; Colecchia M; Lucianò R; Villa L; Mazzone E; Basile G; Scuderi S; Pederzoli F; Bandini M; Barletta F; Larcher A; Capitanio U; Salonia A; Briganti A; Ross JS; Messina A; Montorsi F
Urol Oncol; 2022 Jan; 40(1):10.e1-10.e6. PubMed ID: 34147313
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management.
Pelcovits A; Mueller-Leonhard C; Mega A; Amin A; Kim SP; Golijanin D; Gershman B
World J Urol; 2020 May; 38(5):1243-1252. PubMed ID: 31388818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
